Kornimate/medical-research-clean huggingface dataset:
blood flow restriction therapy following acute shoulder injury patients

Conditions: Shoulder Injury

Summary: atrophy and weakness of the shoulder are a common problem following treatment of a number of shoulder and elbow pathologies. even with relatively short periods of reduced activity, the magnitude of muscle loss can be quite substantial.

blood flow restriction (bfr) therapy is one such therapeutic tool that has received increasing attention, which involves application of a pressurized tourniquet to the injured limb during rehabilitation that limits atrophy when performing strength training with weight that otherwise would not produce enough of a contraction to prevent muscular atrophy. to date, several studies have been performed on bfr therapy, however, the effect of therapy on ligamentous and tendinous injury in the upper extremity remain unclear as most studies have focused on muscular strengthening in healthy individuals and on lower extremity injuries distal to the tourniquet.

Eligibility criteria:
inclusion criteria: * injured patient with clinical and magnetic resonance imaging (mri) consistent with a formal diagnosis of non-operative rotator cuff and/or biceps tendinopathy * no prior upper extremity ipsilateral procedures or history of deep vein thrombosis * those willing to be part of the study exclusion criteria: * patients younger than 18 or older than 55 years of age * a history of revision surgery or prior ipsilateral upper extremity surgery * concomitant ligamentous, tendinous, or cartilage injury that would alter postoperative rehabilitation protocol * inability to comply with the proposed follow-up clinic visits * patients lacking decisional capacity

Keywords: upper extremity injuries muscle atrophy tendinopathy
preoperative oral immunonutrition for patients with pancreatic cancer undergoing elective surgery - effect on complications and length of hospital stay

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to investigate the effect of preoperative immunonutrition on complications and length of hospital stay in patients with pancreatic cancer undergoing elective surgery.


Eligibility criteria:
inclusion criteria: * men and women referred to treatment at surgical gastroenterology clinic c, ward 2122 for pancreatic cancer * age \> 18 years. exclusion criteria: * age \< 18 years * pregnant and lactating women * persons who cannot understand and/or speak danish * renal dysfunction * milk allergy * participants are excluded if elective surgery is not indicated after all

Keywords: postoperative complications elective surgery gi surgery immunonutrition immune-enhancing immune-modulating nutrition pancreatic cancer postoperative complications and length of hospital stay after major gastrointestinal (gi) elective surgery.
adherence to treatment and quality of life in copd

Conditions: Chronic Obstructive Pulmonary Disease; Compliance, Patient; Quality of Life

Summary: the present non-interventional observational study in the greek population aims at collecting the characteristics of copd patients selected to be given the inhaled combination of fluticasone propionate and salmeterol in doses of 100 μg mcg (250 μg) mcg (500 g) mcg through the elpenhaler® device, to investigate (a) the effectiveness of the treatment for compliance and the quality of life of the patients; and (b) the safety of the drugs in patients whose disease is treated either in a hospital or in a private physician.

rolenium® is an inhalable combination the active ingredients of which is the inhaled combination of fluticasone propionate and salmeterol in doses (100 + 50) mcg, (250 + 50) mcg, (500 + 50) mcg administered via the elpenhaler ®, developed by elpen. it has been approved as a bronchodilator therapy for copd (a fast-exiting volume in the first second (fev1) after a bronchodilator less than 60% predicted) with a history of repeated seizures that have significant symptoms despite regular bronchodilator therapy. for copd in adults an inhalation of 500 micrograms of fluticasone propionate and 50 micrograms of salmeterol twice daily is recommended4. more information on the efficacy and safety of the investigational medicinal product is provided in the summary of product characteristics (spc).

Eligibility criteria:
inclusion criteria: * patients to be started on rolenium®, an inhaled combination of fluticasone propionate and salmeterol in doses (100 + 50) mcg, (250 + 50) mcg, (500 + 50) mcg administered via the elpenhaler® * patients who should be diagnosed with severe copd and fev1 \<60% of the expected normal rate and a history of repeated exacerbations that have significant symptoms despite regular bronchodilator therapy: 1. single laba bronchoconstriction 2. under dual bronchoconstriction laba / lama 3. never have received inhaled or systemic corticosteroids (ics) 4. previous ics use in the past may be present, as long as the patient is not in the same treatment for the last three months. * male or female patients over 18 years of age * compliance with treatment * compliance with study procedures * signed informed consent form exclusion criteria: * men or women under 18 years of age * non-compliance with treatment * inappropriate use of inhaled therapies * non-compliance in study procedures * unsigned patient consent
efficacy of aspiration and sclerotherapy during laparoscopy using 95% ethanol for the treatment of endometriomas

Conditions: Endometrioma; Endometriosis

Summary: the purpose of this study is to evaluate the efficacy of aspiration and sclerotherapy during laparoscopy using 95% ethanol for the treatment of endometriomas, compared to the standard cystectomy treatment - a prospective case control study.

women who are candidates for elective laparoscopy for the treatment of ovarian ensometriomas will be assigned to one of two groups - a) standard cystectomy treatment, b) aspiration and sclerotherapy using 95% ethanol. the women will be introduced with both operative options and they will choose which one they prefer. after an elaborate explanation about the study they will sign an informed consent form. the following data will be collected prior the operation: age, gravity \& parity, operative history, general medical history, the cyst size, amh (anti mullerian hormone), afc (antral follicle count), symptoms related to endometriosis (through a questionnaire), fertility history including any fertility treatment in the past and planned pregnancy after the operation. the laparoscopy will take place in meir medical center. in the study group the cyst content will be aspirated and flushed with normal saline. 95% sterile ethanol will be instilled into the cyst through a foley catheter. ethanol will be left in the cyst for a maximum of 15 min then aspirated as completely as possible following normal saline flushing. in the control group we will follow the standard treatment which is cystectomy. the women will be followed 4 and 6 months after the surgery.

Eligibility criteria:
inclusion criteria: * women with endometrial cyst ≥ 4 cm. * candidates for elective laparoscopy due to endometriosis. * age 18-45 years exclusion criteria: * endometrial cyst \< 4 cm. * an emergency surgery. * age \ 45 * women with a history of tubal ovarian abscess (toa). * high index of suspision for ovarian malignancy. * ethanol sensitivity.

Keywords: endometrioma endometriosis sclerotherapy ethanol aspiration laparoscopy
safety and efficacy study of cylindrical abdominoperineal resection to treat rectal cancer

Conditions: Rectal Cancer; Treatment; Postoperative Complications; Neoplasm Recurrence, Local; Survival Rate

Summary: the purpose of this study is to determine whether cylindrical abdominoperineal resection is effective in the treatment of advanced very low rectal cancer

abdominoperineal resection (apr) is still a common operation in patients with tumours less than 6 cm from the anal verge. the perineal phase of apr is a difficult part of the operation, often done with the patient in the supine position.the risk of inadvertent bowel perforation is high, the resulting specimen frequently has a waist at the lower border of the mesorectum, and the circumferential resection margin (crm) is often close to the rectal muscle tube. the cylindrical apr may be performed via an extended posterior perineal approach, that aims to create a more cylindrical specimen without a waist. the potential benefit of this technique is a reduction in the risk of bowel perforation and tumour involvement of the crm, and thus in the risk of local recurrence. perineal wounds in patients following apr are at considerable risk for infection, dehiscence and delayed healing when closed primarily. this can be further increased in patients who have received neoadjuvant chemoradiation therapy. the adoption of extended resection, such as the cylindrical apr, may cause additional risks. the use of acellular biomaterials, including human acellular dermal matrix (hadm) has drawn great interest for the complex abdominal wall reconstruction. the purpose of this study is to determine whether cylindrical abdominoperineal resection is effective in the treatment of advanced very low rectal cancer, and to determine the initial results of pelvic reconstruction using human acellular dermal matrix after cylindrical abdominoperineal resection.

Eligibility criteria:
inclusion criteria: * tumor within 6 cm of the anal verge, or with very narrow pelvis * t3-t4 as determined by preoperative mri or endorectal ultrasonography examination, or a low tumor is fixed or tethered at rectal examination * absence of distant metastases * absence of intestinal obstruction exclusion criteria: * t1-t2 as determined by preoperative mri or endorectal ultrasonography examination * with distant metastases * with intestinal obstruction * pregnancy or lactation * allergic constitution to heterogeneous protein * with operation contraindication * with mental disorder

Keywords: cylindrical abdominoperineal resection rectal cancer acellular dermal matrix pelvic reconstruction circumferential resection margin overall survival
testogel® (testosterone gel 50mg/5g) in the treatment of male hypogonadism

Conditions: Hypogonadism

Summary: the purpose of this study is to evaluate the safety and efficacy of testogel® 50mg/5g gel administered once daily (qd, morning dosing) compared to placebo administered once daily (qd, morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being confirmed by clinical features and biochemical tests. for men with hypogonadism, treatment aims to restore testosterone levels to normal physiological range.


Eligibility criteria:
inclusion criteria: * male ages 18-68 years diagnosed as having testosterone deficiency with clinical symptoms * a morning (8:00-10:00) serum total testosterone concentration of ≤ 300 ng/dl, confirmed by a second measurement of morning serum total testosterone concentration ≤ 300 ng/dl (samples to be taken 1 - 3 weeks apart) exclusion criteria: * abnormal prostate as evidenced by prostatic symptoms, prostatic masses or induration on rectal examination, or elevated levels of prostate specific antigen (psa \> 4ng/ml) or a maximum urine flow rate of less than 12 ml/sec(of a urine volume greater than 150ml) (and/or an international prostate symptom score ipss score \>19) * hematocrit \> 50% * major psychiatric illness * unable to understand the protocol or to give informed consent * use of paroxetine and clomipramine * active alcoholism * history of drug abuse within the past five years; * use of drugs that might interfere with the results of the study (e.g., antiandrogen, estrogens or p 450 enzyme inducers, barbiturates); * bmi \ 30 according to chinese bmi references; * generalized skin disease that may affect absorption of t (e.g., psoriasis) or a known skin intolerance to alcohol; * prolactin \> 40 mcg/l; * untreated severe obstructive sleep apnea;. * uncontrolled or poorly controlled heart failure
trial to examine text-message based mhealth in emergency department patients with diabetes

Conditions: Diabetes

Summary: the investigators propose an innovative, ed-based mhealth intervention: text-med (trial to examine text-based mhealth for emergency department patients with diabetes). text-med is a technologically simple solution using unidirectional daily text messages to consisting of educational materials, trivia questions and challenges promoting healthy lifestyle choices and reminders to check blood sugar, take medications and go to clinic appointments. the investigators believe text-med will improve health outcomes including blood glucose control and encourage weight loss, healthy eating and exercise. text-med is low cost, easy to use and can be quickly adapted to other practice environments.


Eligibility criteria:
inclusion criteria: 1) ≥18 years old 2) have type 2 diabetes 3) have a text message capable mobile phone 4) know how to receive text messages 5) speak and read english or spanish and 6) have a hba1c ≥8%. exclusion criteria: 1) overt psychosis 2) unable to provide informed consent and 3) pregnancy.
pediatric bipolar depression

Conditions: Bipolar Depression

Summary: the purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine xr or seroquel® xr) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with bipolar depression and if so, how it compares with placebo (a non-active tablet, like a sugar pill, that looks like quetiapine).


Eligibility criteria:
inclusion criteria: * provision of informed consent by one or both parents or legal guardian and written assent by the patients before any study procedures are performed. * the patient must have a documented clinical diagnosis for bipolar i or bipolar ii disorder, and including current episode depressed. * patients are required to be in outpatient status at the enrollment and randomization visits and believed likely to remain an outpatient for the duration of the study. * patients must be able to swallow the study medication tablets. exclusion criteria: * the patient must not have been diagnosed with tourette's disorder, obsessive-compulsive disorder, acute post-traumatic stress disorder, panic disorder, autistic disorder and/or asperger's disorder. * patient can not have a history of non-response to an adequate treatment to more than 2 antidepressants during the current episode. * the patient must not have received electroconvulsive therapy (ect) within 30 days before participating in the study. * patients who in your doctors judgement pose a current suicidal or homicidal risk.

Keywords: bipolar depression depression children adolescents seroquel bipolar depression in children and adolescents
verification of the safety of normal food before a cerebral arteriography

Conditions: Cerebral Angiography

Summary: fasting is currently required before elective cerebral angiography, despite numerous arguments against fasting (kidney toxicity, vasovagal reaction, discomfort) and seams unusefull regarding it's main goal : reducing nausea and vomiting. the investigators propose to assess frequency of nausea and vomiting among patients having taken their breakfast at home before day care angiography. the investigators hypothesise that less than 1% of non fasting patients will suffer of vomitint.

fasting is currently required before elective cerebral angiography, despite numerous arguments against fasting (kidney toxicity, vasovagal reaction, discomfort) and seams unusefull regarding it's main goal : reducing nausea and vomiting. the investigators propose to assess frequency of nausea and vomiting among patients having taken their breakfast at home before day care angiography. the investigators hypothesise that less than 1% of non fasting patients will suffer of vomitint.

Eligibility criteria:
inclusion criteria: * adult, * non fasting, * day care hosptilalisation exclusion criteria: * childs, * pregnancy, * parenteral nutrition, * nausea, * vomiting before arteriography, * arteriography under general anesthesia

Keywords: fasting non fasting cerebral angiography nausea vomiting
risk factors and characteristics of covid 19 infection in patients with haematological diseases

Conditions: Covid19

Summary: 1. assessment of risk factor of covid 19 in haematological patients 2. assessment of characteristics of covid 19 in haematological patients

an ongoing outbreak of pneumonia associated with a novel coronavirus, severe acute respiratory syndrome (sars) coronavirus 2, was reported in wuhan, hubei province, china, in december 2019 . in the following weeks, infections spread across china and other countries around the world . the chinese public health, clinical, and scientific communities took action to allow for timely recognition of the new virus and shared the viral gene sequence to the world . on january 30, 2020, the world health organization (who) declared the outbreak a public health emergency of international concern . on february 12, 2020, the who named the disease caused by the novel coronavirus "coronavirus disease 2019" (covid-19) . a group of international experts, with a range of specializations, have worked with chinese counterparts to try to contain the outbreak . preliminary reports suggest that patients with an underlying malignancy have inferior outcomes. while haematology patients are thought to be at increased risk of developing severe complications both due to immune dysfunction from their underlying haematological disorder and immunosuppressive therapies used for treatment, delays in treatment of the underling malignancy may compromise patient safety and survival. data from other cohorts worldwide suggest mortality from covid-19 is higher in haematology patients compared to the general population, with reported mortality rates between 39% and 50% in other british haematology patient cohorts. in particular, a recent uk case series reported significantly higher case fatality rates in haematology patients receiving immunosuppressive or cytotoxic therapy within three months of covid-19 diagnosis, raising concerns about the delivery of systemic anti-cancer therapy (sact) during the pandemic. there is an ongoing need to share collective experience regarding the clinical course of covid-19 in patients with haematological disorders, particularly regarding implications for sact delivery, in order to enable patients to receive treatment in a timely and safe manner during the pandemic.

Eligibility criteria:
inclusion criteria: * patients with haematological diseases who suspected or confirmed to covid 19 infection.. * patients with age more than 18 years old exclusion criteria: * patients under the age of 18. * patients who refuse to contribute in this study.

Keywords: haematological diseases
comparison of the efficacy of shock wave therapy and laser therapy for plantar fasciitis

Conditions: Plantar Fasciitis, Chronic

Summary: the aim of this study was to investigate the effects of extracorporeal shock wave therapy and low-intensity laser therapy on pain, functionality, plantar fascia thickness and balance in patients with plantar fasciitis.

plantar fasciitis is a pathology resulting from inflammation and/or degeneration of the plantar fascia of the sole of the foot. it affects about 10% of the population. it is one of the most common causes of chronic heel pain in the community and there is tenderness to palpation on the medial aspect of the heel bone. patients complain of pain particularly with the first step in the morning and after rest. mechanical overload and overuse can cause inflammation of the fascia. diagnosis is usually made by clinical assessment and no further investigations are required. in this study, 90 patients between the ages of 18 and 65 who meet the inclusion and exclusion criteria will be enrolled and participants will be randomised into 3 groups. the 1st group will be taught eswt and home exercises for 1 session per week for 3 weeks and will be asked to do it every day. the 2nd group will receive 3 sessions of low intensity laser per week for 3 weeks and will be asked to do home exercises every day. the 3rd group will only be taught home exercises and asked to do participants every day for 3 weeks. visual analogue scale, foot function index, plantar fascia thickness measurement with usg and balance parameters will be measured at the beginning of the study, at the end of the treatment and at week 12.

Eligibility criteria:
inclusion criteria: * male and female patients between 18 and 65 years of age, diagnosed with "plantar fasciitis" by anamnesis and physical examination * complaint duration of at least 3 months * patients who agree to participate in the study exclusion criteria: * complaint lasting less than 3 months * injection in the heel area in the last 6 months * use of physiotherapy modalities for the heel in the last 6 months * bilateral complaint * pregnancy * malignancy * epilepsy * history of cardiac pacemaker * anticoagulant use * history of systemic inflammatory disease * history of lower extremity fracture or surgery * existing open wound in the heel area * patient hypersensitivity * systemic infection in the patient * uncontrolled hypertension in the patient * patient inability to cooperate * history of neuromuscular disease affecting balance parameters * unwillingness of the patient to participate in the study

Keywords: rehabilitation extracorporeal shock wave therapy low intensity laser plantar fasciitis
evaluation of musculoskeletal microcirculation with ultrasound

Conditions: Standardised Claudication Treadmill Test

Summary: this study aims to validate the use of dynamic contrast-enhanced ultrasound in measuring the blood supply to the muscles of the leg, and how this changes with exercise and vascular pathology.

we propose a model for the use of dynamic contrast-enhanced ultrasound (dceu) to directly evaluate the microcirculation of the musculoskeletal system. we believe that this will be a valuable research tool into diseases of the microcirculation, and in the future may also offer a clinical benefit by quantifying and monitoring disease over time and after intervention. it may also allow targeting of therapies towards those patients most at risk of ulcers and peripheral neuropathy, and those that would get the maximum benefit from these therapies.

Eligibility criteria:
group 1 - healthy subjects inclusion * 18+ years old exclusion * personal history of diabetes or peripheral arterial disease, current pregnancy, previous surgery to the lower limb, heart attack within 4 weeks, or unstable angina group 2 - peripheral arterial disease subjects inclusion * 18+ years old, radiological evidence of peripheral arterial disease (arterial doppler or angiogram), ankle-brachial pressure index (abpi) 0.5-0.8 exclusion * personal history of diabetes, current pregnancy, previous amputation, heart attack within 4 weeks, or unstable angina group 3 - diabetic subjects inclusion * 18+ years old, with a clinical diagnoses of diabetes (1, 2) exclusion - abpi\<0.9, previous amputation, current pregnancy or breastfeeding, heart attack within 4 weeks, or unstable angina.

Keywords: treadmill test